Heads Up: (RNAZ) Is Locked In On Tomorrow’s Watchlist—Here’s Why

*Sponsored Krypton Street Announces TransCode Therapeutics (Nasdaq: RNAZ) As Its Next Potential Breakout Idea For Tomorrow—Thursday, May 1, 2025 Here’s Why (RNAZ) Just Hit Our Radar… (RNAZ) Recently Moved Approximately 93% Inside Of Nine Sessions, From $0.2196 To $0.425 While Breaking Key Moving Averages. (RNAZ) Float is Listed as Under 21M Shares—Which Could Set The Stage For Big Swing Potential If Demand Begins To Shift.  Analyst Target From HC Wainwright Set At $10 For (RNAZ), Reported By Benzinga, Suggests Over 2,250% Upside Potential. Take A Look At (RNAZ) Before Tomorrow Morning… April 30, 2025 Dear Reader, Following today’s Biotech profile that reached $8.11,  marking an approximate 42% move from yesterday’s $5.68 close, we’re now announcing our next potential breakout idea for tomorrow—Thursday, May 1, 2025. And tomorrow, that spotlight lands squarely on TransCode Therapeutics, Inc. (Nasdaq: RNAZ). Until recently, (RNAZ) was quietly pushing forward in a space dominated by legacy names and immune-based approaches. But that quiet push is starting to generate noise—not from hype, but from clinical traction. TransCode Therapeutics, Inc. (Nasdaq: RNAZ)’s platform targets the genetic core of metastatic cancer using precision-built RNA therapeutics.  Now, their lead candidate isn’t just in human trials—it’s reaching real tumors in real patients.  The transition from theory to measured, in-body activity is already underway. That progress hasn’t gone unnoticed. Just weeks ago, Benzinga reported that HC Wainwright & Co.—one of street’s longest-standing firms—assigned a $10 target to (RNAZ). From today’s open of $0.425, that figure suggests a potential upside of over 2,250%. That $10 target didn’t come out of nowhere. Over the past 9 sessions alone, (RNAZ) has quietly moved approximately 93%, from $0.2196 on April 17 to $0.425 today (April 30, 2025)—pushing above its 5- and 20-day moving averages. With its 50-day moving average still way up at $1.5253, we have all eyes on (RNAZ) right now. But keep in mind, (RNAZ) has less than 21M shares in its float—which could set the stage for potential swings if demand begins to shift. Keep reading to see why (RNAZ) is topping our watchlist tomorrow morning… FDA Steps In With Orphan Designation Backing (RNAZ)’s Lead Candidate… One of the key reasons RNAZ is gaining traction is the recent Orphan Designation granted by the FDA for its lead program in pancreatic cancer—one of the most aggressive and difficult cancers to treat.  This designation not only underscores the urgency and clinical importance of targeting miRNA-10b, a known driver of metastasis, but also reflects clear regulatory alignment behind the company’s approach. Clinical Data Validates (RNAZ)’s Precision-Targeting Platform… That regulatory recognition is being matched by real-world validation. TransCode’s lead therapeutic, TTX-MC138, is currently in a Phase 1a trial—but what makes this program stand out is the signal it delivered even earlier. In a prior Phase 0 microdose study, the compound was shown to reach metastatic lesions in the liver, lungs, and bones of a real human patient. Even at low, subtherapeutic doses, it triggered measurable pharmacodynamic responses in blood samples—early evidence that this therapy is hitting its target inside the body, not just on paper. More Than a Molecule—It’s a Platform… But this isn’t a single-shot pipeline.  TransCode Therapeutics (Nasdaq: RNAZ)’s delivery system has broad potential across multiple RNA modalities, capable of transporting siRNA, antisense oligos, and immunostimulatory payloads with high precision.  The company is already expanding the platform with new candidates—TTX-siPDL1, a checkpoint inhibitor designed to improve immune engagement, and TTX-RIGA, which aims to activate the body’s innate immune response to help eliminate tumors from within. Backing this clinical ambition is animal data that’s hard to overlook. In both murine models and spontaneous feline cancers, TTX-MC138 has delivered complete regressions of metastatic disease and extended survival significantly—even in late-stage cases.  These results speak to the potential power of the platform when it translates from lab to clinic. One Platform. Multiple Targets. (RNAZ) Quietly Builds a Therapeutic Arsenal… On March 27, 2025, TransCode announced that it had initiated dosing in its fourth cohort of the ongoing Phase 1 trial for TTX-MC138. This marks a key step forward in the program, with ten patients now treated at escalating dose levels.  The company’s ability to progress this trial without interruption adds meaningful weight to its early-stage development and reinforces that momentum is not just theoretical—it’s being measured one patient at a time. Now that they’ve proven the delivery system can reach the hardest-to-hit areas—metastatic sites—the company is rolling out new candidates using the same backbone. Their siRNA-based checkpoint inhibitor (TTX-siPDL1) has already shown potential to regress pancreatic tumors by ~90% in animal models when combined with chemo. Another, TTX-RIGA, is being positioned as an immune trigger with possible impact across recurrent or deep-tissue tumors. The pipeline is no longer just one bullet.   It’s a modular platform—one with the potential to address multiple angles of cancer treatment using custom-built RNA tools. And right now, that platform is finally stepping out of the shadows and into the spotlight. With key milestones stacking up—and the clinical picture coming into sharper focus—there’s real reason to be paying attention. 5 Reasons Why TransCode Therapeutics (Nasdaq: RNAZ) Just Hit Our Radar For Tomorrow Morning—Thursday, May 1, 2025… 1. Recent Market Recognition: In just the last 9 sessions, (RNAZ) moved approximately 93%, from $0.2196 on April 17 to $0.425 by April 30, 2025. That kind of move—especially while surpassing its 5 and 20-day moving averages—can signal growing interest and the potential for continued momentum. 2. Analyst Coverage: HC Wainwright & Co., one of the longest-standing names on the street, recently set their target on (RNAZ) at $10, as reported by Benzinga. That figure suggests over 2,250% upside potential. 3. Low Float: With a float reportedly under 21M shares and over $62M raised without excessive dilution, (RNAZ) stands out structurally. That combination—fiscal runway with a tight share count—can often be a potential catalyst if demand begins to shift. 4. Real Human Data in the Clinic—And It’s Delivering: Their lead RNA-based therapeutic, TTX-MC138, has already been evaluated in a human Phase 0 study. Imaging showed the compound reached metastatic lesions in the liver, lung, and bone, and lab results showed significant target activity—demonstrated even at low doses. 5. Recognized by the FDA with Orphan Designation: The FDA granted Orphan Designation for TTX-MC138 in pancreatic cancer—a notoriously difficult disease. This designation supports the seriousness of the science and indicates alignment with regulators focused on unmet needs. What’s Putting (RNAZ) in the Spotlight Right Now… As more attention shifts toward precision-targeted RNA platforms, TransCode Therapeutics (Nasdaq: RNAZ) is quickly emerging as one to keep tabs on. Backed by a $10 target from HC Wainwright & Co. and an approximate 93% move in just nine sessions, the signals aren’t just technical—they’re structural. With fewer than 21M shares in the float, a $62M+ funding base, and human trial data showing real tumor targeting, (RNAZ) is positioned differently than most early-stage names. The FDA’s Orphan Designation, full tumor regression in animal models, and the rollout of new pipeline candidates only strengthen the case. This isn’t just another biotech name—it’s one that’s starting to get attention. We’ll be watching it closely at tomorrow’s open. If you haven’t added (RNAZ) to your radar yet—now might be the time. Expect a quick update from me in the morning. Have a good night. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. *Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 04/30/2025 and ending on 05/01/2025 to publicly disseminate information about (RNAZ:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Media 1717 LLC, TD Media LLC and their member own shares of (RNAZ:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/rnaz-8m3bh/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice